Your browser doesn't support javascript.
loading
Efficacy and safety of an extended-release sebacoyl dinalbuphine ester for laparoscopic cholecystectomy: A randomized controlled trial.
Lee, Ying-En; Fu, Chen-Yu; Shiue, Yow-Ling; Lu, Chu-Yun; Chen, Chung-Yen; Chen, Jian-Han; Chen, Jen-Lung; Lam, Chen-Fuh.
Affiliation
  • Lee YE; Department of Anesthesiology, E-Da Hospital and I-Shou University, Kaohsiung, Taiwan.
  • Fu CY; Institute of Biomedical Sciences, College of Medicine, National Sun Yat-Sen University, Kaohsiung, Taiwan.
  • Shiue YL; Department of Anesthesiology, Shin-Huey-Shin Hospital, Kaohsiung, Taiwan.
  • Lu CY; Department of Anesthesiology, E-Da Hospital and I-Shou University, Kaohsiung, Taiwan.
  • Chen CY; Department of Nursing, I-Shou University College of Medicine, Kaohsiung, Taiwan.
  • Chen JH; Institute of Biomedical Sciences, College of Medicine, National Sun Yat-Sen University, Kaohsiung, Taiwan.
  • Chen JL; Institute of Precision Medicine, College of Medicine, National Sun Yat-Sen University, Kaohsiung, Taiwan.
  • Lam CF; Department of Nursing, I-Shou University College of Medicine, Kaohsiung, Taiwan.
Medicine (Baltimore) ; 102(31): e34423, 2023 Aug 04.
Article in En | MEDLINE | ID: mdl-37543779
ABSTRACT

BACKGROUND:

A long-acting κreceptor agonist parenteral analgesic may theoretically improve acute pain and reduce incidence of chronic postsurgical pain (CPSP) after laparoscopic cholecystectomy with minimal drug-related side effects of the traditional µreceptor opioids.

METHODS:

Eighty adult patients undergoing elective laparoscopic cholecystectomy were randomly assigned to receive single intramuscular injection of an extended-release sebacoyl dinalbuphine ester (SDE, Naldebain 150 mg; n = 40) or placebo (n = 40) after anesthesia induction. Standard multimodal analgesia (MMA) was administered for postoperative pain control. The primary endpoint was pain intensity within 7 days after surgery. The secondary endpoints were incidence CPSP at 3 months and adverse reactions up to 7 days after surgery.

RESULTS:

The highest visual analogue scale (VAS) and area under the curve of VAS 0 to 48 hours after operation were not different between the two groups and a similar proportion of patients requested rescue parenteral analgesics. Average pain intensities were also not different at 72 hours and 7 days after surgery. Incidence of CPSP was 22.5% and 13.1% in patients who received placebo and SDE treatment, respectively (P = .379). Significantly higher incidence of drug-related adverse events, including dizziness, nausea and injection site reactions, were recorded in the SDE group.

CONCLUSION:

A single dose of extended-release analgesic SDE given intraoperatively did not provide sufficient add-on effect for acute and chronic pain management after laparoscopic cholecystectomies in patients who received standard postoperative MMA. Intramuscular injection of 150 mg SDE in patients with average body mass causes adverse events that could have been overlooked. More clinical studies are warranted to determine the target populations who may benefit from SDE injections for improvement of acute and chronic postsurgical pain management.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cholecystectomy, Laparoscopic / Nalbuphine Type of study: Clinical_trials / Prognostic_studies Limits: Adult / Humans Language: En Journal: Medicine (Baltimore) Year: 2023 Document type: Article Affiliation country: Taiwan

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cholecystectomy, Laparoscopic / Nalbuphine Type of study: Clinical_trials / Prognostic_studies Limits: Adult / Humans Language: En Journal: Medicine (Baltimore) Year: 2023 Document type: Article Affiliation country: Taiwan